トリロスタン
参考資料

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29  “Trilostane in advanced breast cancer”. Expert Opin Pharmacother 7 (17):  2413–9. (December 2006). doi:10.1517/14656566.7.17.2413. PMID 17109615.
1 2  J. Elks (14 November 2014). The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies. Springer. pp. 1245–. ISBN 978-1-4757-2085-3. https://books.google.com/books?id=0vXTBwAAQBAJ&pg=PA1245
1 2  I.K. Morton; Judith M. Hall (6 December 2012). Concise Dictionary of Pharmacological Agents: Properties and Synonyms. Springer Science & Business Media. pp. 281–. ISBN 978-94-011-4439-1. https://books.google.com/books?id=tsjrCAAAQBAJ&pg=PA281
↑  Martin Negwer (1987). Organic-chemical Drugs and Their Synonyms: (an International Survey). VCH Publishers. ISBN 978-0-89573-552-2. https://books.google.com/books?id=k6fwAAAAMAAJ. "5870 (6516) C20H2:NOs 13647-35-3 42,5-Epoxy-173-hydroxy-3-oxo-50-androstane-22carbonitrile = (22,42,52,173)-4,5-Epoxy-17-hydroxy-3-oxoandrostane-2-carbonitrile (e) S Desopan, Modrastane, Modrenal, Trilostane”, Trilox, Win 24 540, Winstan U Adrenocortical suppressant (steroid biosynthesis inhibitor)"
↑  George W.A Milne (8 May 2018). Drugs: Synonyms and Properties: Synonyms and Properties. Taylor & Francis. pp. 34–. ISBN 978-1-351-78989-9. https://books.google.com/books?id=xUlaDwAAQBAJ&pg=PT34
1 2 3  “Possible therapeutic effect of trilostane in rodent models of inflammation and nociception”. Curr Ther Res Clin Exp 75:  71–6. (December 2013). doi:10.1016/j.curtheres.2013.09.004. PMC 3898193. PMID 24465047. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3898193/.
↑  “Cushing's Disease in Dogs Part 3: Current & Investigative Options for Therapy” (英語). Today's Veterinary Practice (2016年2月24日). 2021年1月4日閲覧。
1 2 3 4 5 6 7 8  “デソパン錠60mg 添付文書”. www.pmda.go.jp.   PMDA. 2021年8月21日閲覧。
1 2 3  “Trilostane treatment in dogs with pituitary-dependent hyperadrenocorticism”. Australian Veterinary Journal 81 (10):  600–7. (October 2003). doi:10.1111/j.1751-0813.2003.tb12498.x. PMID 15080470. http://caninediabeteswiki.wikkii.com/wiki/File:Australian_veterinary_journal_october_2003.pdf 5 April 2011閲覧。.  (PDF)
1 2  “Treating Cushing's Disease in Dogs”.   US Food and Drug Administration. 3 April 2011閲覧。
1 2 3  “Vetoryl-Contraindications”.   NOAH Compendium of Animal Health-National Office of Animal Health UK. 3 April 2011閲覧。
1 2  “Dechra US Datasheet-Vetoryl”.   Dechra US. 3 April 2011閲覧。 (PDF)
↑  “Cushing's Disease in Dogs” (英語). NASC LIVE. 2021年1月4日閲覧。
↑  de Gier J; Wolthers CH; Galac S; Okkens AC; Kooistra HS (April 2011). “Effects of the 3β-hydroxysteroid dehydrogenase inhibitor trilostane on luteal progesterone production in the dog”. Theriogenology 75 (7):  1271–9. doi:10.1016/j.theriogenology.2010.11.041. PMID 21295836.
↑  Reusch, Claudia E. (2006年). “Trilostane-5 Years of Clinical Experience for the Treatment of Cushing's Disease”.   Ohio State University Endocrinology Symposium. pp. 17–19. 5 April 2011閲覧。 (PDF)
↑  Reusch, Claudia E. (2010年). “Trilostane-A Review of a Success Story”.   World Small Animal Veterinary Association (WSAVA). 5 April 2011閲覧。
↑  “Inhibition of progesterone secretion with trilostane for mid-trimester termination of pregnancy: randomized controlled trials”. Human Reproduction (Oxford, England) 17 (6):  1483–9. (June 2002). doi:10.1093/humrep/17.6.1483. PMID 12042266. http://humrep.oxfordjournals.org/cgi/pmidlookup?view=long&pmid=12042266.
1 2  “Non-competitive steroid inhibition of oestrogen receptor functions”. Int. J. Cancer 101 (1):  17–22. (September 2002). doi:10.1002/ijc.10547. PMID 12209583.
1 2  Glover, Hilary R.; Barker, Stewart; Malouitre, Sylvanie D. M.; Puddefoot, John R.; Vinson, Gavin P. (2010). “Multiple Routes to Oestrogen Antagonism”. Pharmaceuticals 3 (11):  3417–3434. doi:10.3390/ph3113417. ISSN 1424-8247.
↑  “Trilostane, an inhibitor of 3β-hydroxysteroid dehydrogenase, has an agonistic activity on androgen receptor in human prostate cancer cells”. Cancer Lett. 297 (2):  226–30. (November 2010). doi:10.1016/j.canlet.2010.05.015. PMID 20831980.
↑  “デソパン錠60mg インタビューフォーム”. www.pmda.go.jp.   PMDA. 2021年8月21日閲覧。
1 2  Cook, Audrey K. (1 February 2008). “Trilostane: A therapeutic consideration for canine hyperadrenocorticism”.   DVM 360. 5 April 2011閲覧。
↑  “Trilostane consumer information”.   Drugs.com (4 January 2009). 12 February 2008時点のオリジナルよりアーカイブ。3 April 2011閲覧。
↑  “Modrenal consumer information”.   Drugs.com UK. 3 April 2011閲覧。
↑  “Modrenal”.   electronic Medicines Compendium UK. 3 April 2011閲覧。
↑  “Vetoryl approval information”.   Food and Drug Administration (5 December 2008). 3 April 2011閲覧。
↑  Hillier, Andrew (2006年). “Alopecia: Is an Endocrine Disorder Responsible?”.   Ohio State University Endocrinology Symposium. p. 12 of 67. 8 April 2011閲覧。 (PDF)
↑  Cerundolo, Rosario; Lloyd, David H.; Persechino, Angelo; Evans, Helen; Cauvin, Andria (2004). “Treatment of Canine Alopecia X with trilostane”. Veterinary Dermatology (European Society of Veterinary Dermatology) 15 (5):  285–93. doi:10.1111/j.1365-3164.2004.00403.x. PMID 15500480. http://www.solidgoldsamoyeds.com/Treatment%20with%20trilostane.pdf 16 May 2011閲覧。.  (PDF)
トリロスタンは3β-HSDを阻害する。